Adrenocorticosteroids and Adrenocortical Antagonists
Adrenocorticosteroids and Adrenocortical Antagonists
Adrenocorticosteroids and Adrenocortical Antagonists
and
Adrenocortical Antagonists
Ma. Victoria M. Villarica, M.D.
Fatima College of Medicine
Adrenal Gland
• Adrenal cortex – mineralocorticoids,
glucocorticoids, adrenal androgens
(androstenedione and
dehydroepiadrosterone)
• Adrenal medulla - catecholamines
Adrenal Cortex
• Outer zone (zona glomerulosa) – secretes
mineralocorticoids
- receptors for angiotensin II and express
aldosterone synthase; do not atrophy
• Inner zone (zona fasciculata and
reticularis) – secrete glucocorticoids and
adrenal androgens
- expresses 17α-hydroxylase and 11β-
hydroxylase; results in atrophy
ACTH
• a peptide of 39 amino acids
• amino acids 15 – 18: high affinity binding
• amino acids 6 – 10: receptor activation
• synthesized from pro-opiomelanocortin
(POMC)
ACTH
• Stimulates the synthesis and release of
adrenocortical hormones
• Human ACTH – G-protein coupled
receptor family → activates adenyl cyclase
→ ↑ intracellular cyclic AMP (2nd
messenger for most steroidogenesis)
Regulation of ACTH secretion
• Hypothalamic – Pituitary – Adrenal axis
(HPA axis)
- 3 levels of regulation:
1. diurnal rhythm in basal steroidogenesis
2. negative feedback regulation
3. marked increases in steroidogenesis in
response to stress
Steroid hormone production
• rate limiting step – conversion of
cholesterol to pregnanolone
• sources of cholesterol: circulating
cholesterol (LDL), cholesterol esterase, de
novo biosynthesis
Adrenal Cortex
• Produce and releases natural
adrenocortical hormones
• Uses:
a. diagnosis and treatment of disorders of
adrenal function
b. treatment of inflammatory and
immunologic disorders
Adrenocorticosteroids
Classification:
A. Mineralocorticoids
B. Glucocorticoids
C. Gonadal Androgens
A. Glucocorticoids
Naturally-occurring: Cortisol
Kinetics: 10-20 mg daily; circadian
rhythm;
bound to CBG (90%), albumin (5%);
t ½ =60-90 mins.; liver; 1/3 excreted as
dihydroxyketone metabolites
B. Mineralocorticoids
Kinetics:
source – cholic acid (cattle) or steroid
sapogenins (diosgenin, hecopenin);
absorption: oral, IV, IM, sites of local
administration
prolonged effects: occlusive dressing,
large areas – may cause suppression of
HPA axis
Kinetics (cont.)
• Transport: 90% bound to CBG (transcortin
– high affinity but low total binding
capacity) and albumin (low affinity but high
binding capacity)
10% unbound
• Metabolism – liver
• Excretion - kidneys
Therapeutic Uses:
A. Replacement Therapy
1. Adrenal Insufficiency
a. Acute adrenal insufficiency
ssx: GIT symptoms, dhn, hypoNa, hyperK, weakness, lethargy,
hypotension
cause: disorder of the adrenal
abrupt withdrawal of glucocorticoids at high doses or
prolonged use
mgt: IV : D5 0.3%NaCl solution
Monitor for fluid overload
Hydrocortisone (cortisol) 100mg bolus, ffed by 100mg every
8 hrs. ; once stable, may give 25mg IM hydrocortisone every 6-
8hrs.; thereafter, same mgt with chronic adrenal insufficiency
1. Adrenal Insufficiency (cont.)
b. Chronic Adrenal Insufficiency (Addison’s disease)
ssx:hyperpigmentation, wt. loss, inability to
maintain fasting blood sugar, weakness, fatigue,
hypotension
cause: primary adrenal insufficiency, tuberculosis
mgt: Hydrocortisone 20-30mg/day BID
Fludrocortisone acetate 0.05 – 0.2mg/day
(valuable indicator of adequate replacement:
disappearance of hyperpigmentation and
resolution of electrolyte abnormalities)
-monitor plasma ACTH levels or measure
urinary free cortisol; dosage adjustments for
stress
Therapeutic Uses (cont.)
2. Adrenocortical hypo- and hyperfunctioning
a. Congenital Adrenal Hyperplasia
ssx: after puberty with infertility, hirsutism, amenorrhea and
acne; female pseudohermaphroditism; accelerated
linear growth but height at maturity is reduced; salt
wasters – CV collapse (volume depletion)
cause: Genetic disorder; activity of enzymes required for
the biosynthesis of corticosteroid is deficient (21 β hydroxylase)
mgt: 1st seen as acute adrenal crisis
oral hydrocortisone 0.6mg/kg/day BID or TID
fludrocortisone acetate 0.05-0.2mg/day
treatment in-utero: mothers at risk – glucocorticoid
therapy is initiated before 10 weeks gestation ffed by
genotyping and sex determination
b. Cushing’s syndrome
cause: pituitary adenoma, tumors of the adrenal
gland
ssx: round, phletoric face, truncal obesity,
muscle wasting, thinning, purple striae and easy
bruising of the skin, poor wound healing,
osteoporosis
mgt: surgery
hydrocortisone 300 mg IV on the day of the
surgery, then maintenance oral dose
B. Stimulation of fetal lung maturation –
betamethasone 12mg ffed by 12mg
18-24 hrs. later
C.Nonendocrine Diseases
1. Rheumatic disorders – suppress the disease
and minimize resultant tissue damage
mgt: prednisone 10 mg/kg/day (taper
thereafter by decreasing 1mg/kg/day every
2-3 wks)
intraarticular injection: triamcinolone
acetonide
osteoarthritis : intraarticular injections
with interval of 2-3 mos. to
minimize complications
C. Non-Endocrine Diseases (cont.)
1. Spirinolactone – diagnosis of
aldosteronism (400-500mg/day fro 4-8
days); preparing for surgery (300-
40mg/day x 2 wks to reduce the incidence
of arrhythmias); hirsutism in women
(androgen antagonist 50-200mg/d x 2-6
mos); diuretic
2. Eplerenone – in clinical trials
3. Drospirenone – progestin in a new oral
contraceptive, antagonizes the effect of
aldosterone
Classification of
Adrenocorticosteroids
I. Short to medium-acting glucocorticoids:
a. Hydrocortisone (cortisol)
b. Cortisone
c. Prednisone
d. Prednisolone
e. Methylprednisolone
f. Meprednisone
II. Intermediate-acting glucocorticoids
a. Triamcinolone
b. Paramethasone
c. Fluprednisolone
III. Long-acting glucocorticoids
a. Betamethasone
b. Dexamathasone
IV. Mineralocorticoids
a. Fludrocortisone
b. desoxycorticosterone acetate
Addison described :
. general languor and debility
. remarkable feebleness of the heart's action
. irritability of the stomach
. peculiar change of the color of the skin
Thank You